118 related articles for article (PubMed ID: 4038378)
1. Erythrocyte mean corpuscular volume during cytotoxic therapy and the risk of secondary leukemia.
de Gramont A; Rioux E; Drolet Y; Delage JM
Cancer; 1985 Feb; 55(3):493-5. PubMed ID: 4038378
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Petru E; Schmähl D
Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
[TBL] [Abstract][Full Text] [Related]
3. Study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in Hodgkin's disease.
de Gramont A; Rioux E; Drolet Y; Delage JM
Cancer Treat Rep; 1984 Dec; 68(12):1467-70. PubMed ID: 6509452
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's disease.
de Gramont A; Louvet C; Krulik M; Smadja N; Donadio D; Laporte JP; Brissaud P; Delâge JM; Drolet Y; Rioux E
Cancer; 1987 Jan; 59(2):301-4. PubMed ID: 3467821
[TBL] [Abstract][Full Text] [Related]
5. [Changes in the mean corpuscular volume during the cytotoxic treatment of cancer and risk of secondary leukemia. Preliminary results].
de Gramont A; Rioux E; Drolet Y; Barry A; Delage JM
Sem Hop; 1984 Mar; 60(14):961-6. PubMed ID: 6326284
[TBL] [Abstract][Full Text] [Related]
6. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
7. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid drugs: their role in oncological practice.
Lowenthal RM; Jestrimski KW
Med J Aust; 1986 Jan; 144(2):81-5. PubMed ID: 2417096
[No Abstract] [Full Text] [Related]
9. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
10. Second cancers following antineoplastic therapy.
Dorr FA; Coltman CA
Curr Probl Cancer; 1985 Feb; 9(2):1-43. PubMed ID: 3888536
[TBL] [Abstract][Full Text] [Related]
11. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
12. [Acute leukemia in patients treated for Hodgkin's disease].
Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
[No Abstract] [Full Text] [Related]
13. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
14. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
15. Incidence of second cancers in patients treated for Hodgkin's disease.
Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
[TBL] [Abstract][Full Text] [Related]
16. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
[TBL] [Abstract][Full Text] [Related]
18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced Hodgkin's disease.
Straus DJ
Hematol Oncol Clin North Am; 1989 Jun; 3(2):287-302. PubMed ID: 2473061
[TBL] [Abstract][Full Text] [Related]
20. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
